NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: METROPOLIS · data 2026-10-30
Metropolis Healthcare Ltd.
In plain words
Price: 10.4% below its 52-week high of ₹609.05.
Delivery: 54.7% of traded shares were kept for delivery over the last 10 sessions, against 54.9% over the last 60.
Latest results: a net profit of ₹57 cr for the quarter ended Jun 2026 (+25.8% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,710 cr |
| Net profit (last 12 months) | ₹202 cr |
| Sales growth, 3 years (yearly) | 12.8% |
| Profit growth, 3 years (yearly) | 10.0% |
Latest results in brief (Q1 FY27)
METROPOLIS Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹450.21 crore, up 16.6% YoY and up 6% QoQ.
Net profit was ₹56.67 crore, up 25.8% YoY and up 11.3% QoQ.
Operating margin was 24.7% (23.2% a year ago).
EPS was ₹2.73, up 25.8% YoY and up 11% QoQ.
METROPOLIS के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹450.21 करोड़; पिछले साल की तुलना में 16.6% की बढ़त, पिछली तिमाही की तुलना में 6% की बढ़त।
शुद्ध मुनाफ़ा: ₹56.67 करोड़; पिछले साल की तुलना में 25.8% की बढ़त, पिछली तिमाही की तुलना में 11.3% की बढ़त।
ऑपरेटिंग मार्जिन: 24.7% (एक साल पहले 23.2%)।
EPS: ₹2.73; पिछले साल की तुलना में 25.8% की बढ़त, पिछली तिमाही की तुलना में 11% की बढ़त।
METROPOLISના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹450.21 કરોડ; ગયા વર્ષની સરખામણીએ 16.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6% વધારો.
ચોખ્ખો નફો: ₹56.67 કરોડ; ગયા વર્ષની સરખામણીએ 25.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11.3% વધારો.
ઓપરેટિંગ માર્જિન: 24.7% (એક વર્ષ પહેલાં 23.2%).
EPS: ₹2.73; ગયા વર્ષની સરખામણીએ 25.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 57.4% over the last 20 sessions vs 54.9% in the 40 before (1.05x); shares delivered per day 0.89x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results ● Dividend ● Bonus
- 22 Sept 26Insider SAST disclosure: Franklin Templeton Mutual Fund (thr… acquired 7,42,409 shares -1.3% next session
- 4 Aug 26Results Q1 FY27 results: profit +25.8% YoY -3.3% next session
- 19 May 26Dividend Dividend ₹1 (ex-date) +2.1% next session
- 13 May 26Results Q4 FY26 results: profit +74.7% YoY -1.4% next session
- 20 Mar 26Bonus Bonus 3:1 (ex-date)
- 4 Feb 26Results Q3 FY26 results: profit +32.0% YoY +3.6% next session
- 11 Nov 25Dividend Dividend ₹4 (ex-date) +2.1% next session
- 4 Nov 25Results Q2 FY26 results: profit +13.2% YoY +0.1% next session
- 7 Aug 25Results Q1 FY26 results: profit +18.7% YoY -2.3% next session
- 13 May 25Results Q4 FY25 results: profit −20.0% YoY -5.7% next session
- 4 Feb 25Results Q3 FY25 results: profit +15.5% YoY +2.9% next session
- 8 Nov 24Results Q2 FY25 results: profit +31.2% YoY +2.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹450 cr | ₹57 cr | +25.8% | 24.7% | 2.73 |
| Mar 2026 | ₹425 cr | ₹51 cr | +74.7% | 25.4% | 2.46 |
| Dec 2025 | ₹406 cr | ₹41 cr | +32.0% | 23.4% | 7.99 |
| Sept 2025 | ₹429 cr | ₹53 cr | +13.2% | 25.2% | 10.17 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 47.82% | 48.86% | 48.87% | 48.88% |
| Foreign institutions (FII) | 11.67% | 11.03% | 10.43% | 11.69% |
| Domestic institutions (DII) | 35.49% | 35.12% | 35.79% | 34.73% |
| Mutual funds | 33.09% | 32.67% | 33.28% | 32.22% |
| Retail investors | 3.33% | 3.29% | 3.21% | 3.87% |
| Number of shareholders | 50,592 | 50,636 | 49,175 | 46,670 |
Common questions
What was Metropolis Healthcare Ltd.'s latest quarterly profit?
Metropolis Healthcare Ltd. reported a net profit of ₹57 cr for the quarter ended Jun 2026 (+25.8% on the same quarter a year earlier), on revenue of ₹450 cr.
How much do promoters hold in Metropolis Healthcare Ltd.?
Promoters held 47.82% of Metropolis Healthcare Ltd. at the end of Sept 2026, with 1.21% of promoter shares pledged.
Is Metropolis Healthcare Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.15.
What is Metropolis Healthcare Ltd.'s P/E ratio?
About 56.2, based on the last 12 months' earnings and a price of ₹545.65 (data 2026-10-30).
What is the 52-week high and low of Metropolis Healthcare Ltd.?
The 52-week high is ₹609.05 and the 52-week low is ₹412.25.
Mutual funds holding Metropolis Healthcare Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 4 schemes holding about ₹78 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE LARGE & MID CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.10% | ₹62 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.48% | ₹16 cr |
| ADITYA BIRLA SUN LIFE RETIREMENT FUND - THE 50S PLAN | Aditya Birla Sun Life Mutual Fund | 1.22% | ₹0 cr |
| ADITYA BIRLA SUN LIFE CONSERVATIVE HYBRID FUND | Aditya Birla Sun Life Mutual Fund | 0.01% | ₹0 cr |
Similar companies
Dr. Agarwal's Health Care Ltd. (AGARWALEYE) · Vijaya Diagnostic Centre Ltd. (VIJAYA) · Thyrocare Technologies Ltd (THYROCARE) · Nephrocare Health Services Limited (NEPHROPLUS) · Jeena Sikho Lifecare Limited (JSLL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open METROPOLIS in NSE Scanner →